Journal Name: Clinical Chemistry and Laboratory Medicine (CCLM) Issue: Ahead of print
I spent my early and mid-career years working in a pediatric intensive care unit (PICU) at a large academic center. We did almost everything except for a few things esoteric at the time — small bowel transplants, a few kinds of experimental surgery. I’m now in my late career (but have no plans to quit […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more.
AbstractThe foundation of the treatment of heart failure with reduced ejection fraction is a number of pharmacotherapies shown to reduce morbidity and mortality in large randomised multinational clinical trials. These include angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists, and more recently, a combined angiotensin receptor blocker neprilysin inhibitor, sacubitril/valsartan. In select cases, digoxin, ivabradine and hydralazine with isosorbide dinitrate have a role to play in the treatment of heart failure with reduced ejection fraction. On this ...
ConclusionEfforts to improve QOL30 of HSCT patients and caregivers in the confined environment of an HHH should focus on patients with low baseline QOL and older patients.
Publication date: Available online 9 December 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Jean El-Cheikh, Rana Salem, Radwan Massoud, Charelle Salem, Nohra Ghaoui, Souha S. Kanj, Rami Mahfouz, Ali Bazarbachi
Publication date: Available online 9 December 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Ghulam Rehman Mohyuddin, John Roller, Leyla Shune, Tara Lin, Ajoy Dias, Siddhartha Ganguly, Sunil Abhyankar, Joseph McGuirk, Anurag Singh
Condition: Dexmedetomidine, Liver Transplantation, Allograft Function, Survival Interventions: Drug: Dexmedetomidine; Drug: Saline Sponsor: RenJi Hospital Recruiting
Publication date: Available online 10 December 2018Source: Antiviral ResearchAuthor(s): Long Tan, Noriaki Sato, Atsuko Shiraki, Motoko Yanagita, Yoshihiro Yoshida, Yoshinori Takemura, Kimiyasu ShirakiAbstractEverolimus is an inhibitor of mammalian target of rapamycin (mTOR) and reduces the risk of cytomegalovirus (CMV) infection in transplant recipients. Everolimus inhibits mTOR complex 1, which regulates factors involved in several crucial cellular functions and is required for CMV replication. However, it is not clear how everolimus regulates CMV replication and prevents and alleviates CMV infection. Effects of everolimu...
MONDAY, Dec. 10, 2018 -- Transplant patients with hearts from donors with hepatitis C virus (HCV) infection and obese donors have similar survival rates as patients with other donor hearts, according to two studies published in the December issue...